Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.7590
-0.0610 (-7.44%)
At close: Jun 27, 2025, 4:00 PM
0.7450
-0.0140 (-1.84%)
After-hours: Jun 27, 2025, 7:59 PM EDT

Company Description

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics.

It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022.

Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Revelation Biosciences, Inc.
Revelation Biosciences logo
Country United States
Founded 2020
Industry Biotechnology
Sector Healthcare
Employees 9
CEO James Rolke

Contact Details

Address:
4660 La Jolla Village Drive, Suite 100
San Diego, California 92122
United States
Phone (650) 800-3717
Website revbiosciences.com

Stock Details

Ticker Symbol REVB
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001810560
CUSIP Number 76135L101
ISIN Number US76135L5075
Employer ID 84-3898466
SIC Code 2834

Key Executives

Name Position
James M. Rolke Chairman and Chief Executive Officer
Chester Stanley Zygmont III Chief Financial Officer and Corporate Secretary
Sandra Vedrick Vice President of Human Resources and Investor Relations
Carol Odle Senior Director of Clinical Projects

Latest SEC Filings

Date Type Title
Jun 25, 2025 8-K Current Report
Jun 9, 2025 DEF 14A Other definitive proxy statements
Jun 4, 2025 8-K Current Report
May 29, 2025 PRE 14A Other preliminary proxy statements
May 29, 2025 424B3 Prospectus
May 28, 2025 EFFECT Notice of Effectiveness
May 28, 2025 8-K Current Report
May 23, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
May 20, 2025 S-1 General form for registration of securities under the Securities Act of 1933
May 8, 2025 8-K Current Report